301 related articles for article (PubMed ID: 21091976)
1. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
Antonarakis ES; Chen Y; Elsamanoudi SI; Brassell SA; Da Rocha MV; Eisenberger MA; McLeod DG
BJU Int; 2011 Aug; 108(3):378-85. PubMed ID: 21091976
[TBL] [Abstract][Full Text] [Related]
2. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
Antonarakis ES; Feng Z; Trock BJ; Humphreys EB; Carducci MA; Partin AW; Walsh PC; Eisenberger MA
BJU Int; 2012 Jan; 109(1):32-9. PubMed ID: 21777360
[TBL] [Abstract][Full Text] [Related]
3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
4. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
5. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
6. PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Markowski MC; Chen Y; Feng Z; Cullen J; Trock BJ; Suzman D; Antonarakis ES; Paller CJ; Rosner I; Han M; Walsh PC; Partin AW; Eisenberger M
Clin Genitourin Cancer; 2019 Dec; 17(6):470-475.e1. PubMed ID: 31530439
[TBL] [Abstract][Full Text] [Related]
7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
8. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
13. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
Lepor H; Cheli CD; Thiel RP; Taneja SS; Laze J; Chan DW; Sokoll LJ; Mangold L; Partin AW
BJU Int; 2012 Jun; 109(12):1770-5. PubMed ID: 21992499
[TBL] [Abstract][Full Text] [Related]
15. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
16. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
17. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
18. Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy.
Kim DK; Koo KC; Lee KS; Hah YS; Rha KH; Hong SJ; Chung BH
J Korean Med Sci; 2018 Nov; 33(45):e285. PubMed ID: 30402050
[TBL] [Abstract][Full Text] [Related]
19. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
20. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
